[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kaohsiung Medical University Chung-Ho Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":627},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,45,73,102,128,152,175,202,229,257,278,300,320,345,375,394,426,449,475,503,524,544,567,585,609],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100645253","phase-1-phase-ibiia-open-label-study-to-evaluate-safety-tolerability-and-antitumor-activity-of-hcb101-in-combination-with-multiple-agents-in-subjects-with-advanced-gastric-or-gastro-esophageal-gej-adenocarcinoma-100645253",false,"NCT07680569","Phase Ib\u002FIIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma","HCB101 GC GEJ","Inclusion Criteria:\n\n1. Subjects are able to understand and willing to provide signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, including study visits and study-related procedures.\n2. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.\n3. With histologically\u002Fcytologically confirmed diagnosis of advanced gastric and gastro-esophageal adenocarcinoma as described below:\n\n   • Unresectable locally advanced, or metastatic HER2 (-) gastric or GEJ adenocarcinoma cancer, whose tumors are CLDN 18.2 positive (defined as ≥ 75% of tumor cells demonstrating moderate to strong membranous CLDN 18.2 immunohistochemical staining using an FDA-approved test ( http:\u002F\u002Fwww.fda.gov\u002FCompanionDiagnostics).\n4. Must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n5. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at Screening.\n6. Have a life expectancy of ≥12 weeks (according to the Investigator's judgment).\n7. Have adequate organ function, as indicated by the following laboratory parameters below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days before the administration of the first dose of study intervention).\n\n   1. Absolute neutrophil count ≥1.5 × 109\u002FL\n   2. Platelets ≥100 × 109\u002FL\n   3. Hemoglobin ≥9.0 g\u002FdL\n   4. Total bilirubin ≤1.5 × upper limit of normal (ULN), \\\u003C3.0 × ULN if known Gilbert's disease\n   5. Alanine aminotransferase and aspartate aminotransferase ≤3× ULN and ≤5× ULN for subjects with liver metastasis\n   6. Creatinine clearance ≥30 mL\u002Fmin (using Cockcroft Gault equation)\n   7. Coagulation: International normalized ratio (INR), prothrombin time (PT), and activated partial thromboplastin time (aPTT) ≤1.5× ULN (The INR applies only to subjects who do not receive therapeutic anticoagulation)\n8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test during the Screening Period (within 7 days before the first dose of the study intervention).\n9. Subjects must have tumors that are not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).\n10. Subjects must not have received any prior systemic anti-cancer and immune checkpoint inhibitor therapy.\n\nExclusion Criteria:\n\n1. Medical Conditions:\n\n   1. With a known history of hypersensitivity to any components of the study intervention.\n   2. Subjects who have other malignancies requiring treatment within 2 years before the first dose of study intervention will be excluded, except for radically treated locally curable basal or squamous cell skin cancer and other malignancies that have been treated with no relapse within 2 years.\n   3. Primary tumor in the central nervous system (CNS), or active or untreated CNS metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate, provided they are clinically stable for at least 28 days and have no evidence of new or enlarging brain metastases and no requirements for high-dose corticosteroids 14 days before dosing with study intervention. Subjects on low-dose corticosteroids (\\\u003C20 mg prednisone or equivalent per day) may participate.\n   4. Clinically significant cardiovascular condition, including\n\n      1. History of congestive heart failure (New York Heart Association Class \\>2), with only heart failure with preserved ejection fraction (HFpEF) included;\n      2. History of unstable angina within 6 months before the first dose of study intervention;\n      3. New-onset angina or myocardial infarction within 6 months before the first dose of study intervention;\n      4. New-onset of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia within 6 months before the first dose of study intervention and still in unstable condition and requiring treatment or intervention. History of atrial fibrillation, supraventricular arrhythmia, or ventricular arrhythmia will be allowed, provided the condition is stably controlled.\n   5. History or presence of an abnormal ECG that, in the Investigator's opinion, is clinically meaningful (including QT interval corrected for heart rate using Fridericia's correction \\[QTcF\\] \\>470 msec at Screening, pacemaker installation, or previous diagnosis of congenital long QT syndrome).\n   6. Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia (Note: subjects with chronic Grade 2 toxicities which are well managed and stable may be eligible per the discretion of the Investigator, e.g., Grade 2 chemotherapy-induced neuropathy.)\n   7. With known inherited or acquired bleeding disorders or bleeding diathesis.\n   8. Have RBC transfusion dependence defined as requiring more than 2 units of RBC transfusions every 28 days over a period of 3 months before Screening.\n   9. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.\n2. Prior\u002FConcomitant Therapy\u002FTreatment\n\n   1. Subjects who have undergone major surgery or radical radiotherapy within 28 days before the first dose of study intervention.\n   2. Subjects who have undergone palliative radiotherapy within 14 days before the first dose of study intervention.\n   3. Subjects who have used a radioactive drug (Strontium, Samarium, etc.) within 56 days before the first dose of the study intervention.\n   4. Subjects who have undergone any investigational or approved systemic cancer therapy (including chemotherapy, immunotherapy, hormonal therapy, and herbal\u002Falternative therapies with anti-cancer indications or targeted therapy) within 14 days or 5 half-lives, whichever is longer, before the first dose of the study intervention.\n   5. Subjects who have used herbal medication within 14 days before the first dose of the study intervention.\n   6. Subjects who are active using of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on a case-by-case basis. Daily low dose of aspirin use (≤ 100 mg\u002FQD) is allowed.\n   7. Subjects who have received any treatment targeting the CD47 or SIRPα pathway.\n3. Participation in another clinical study with an investigational product administered in the last 14 days or 5 half-lives (whichever is longer) before receiving the first dose of study intervention. An investigational device was used within 28 days before the first dose of study intervention.\n4. Reproductive and breastfeeding\n\n   1. Women of reproductive potential who are unable to use effective contraception during treatment and for 6 months after the last dose.\n   2. Women who are breastfeeding during treatment and for 6 months after the last dose.\n5. Infections:\n\n   1. An uncontrolled acute infection, an active infection requiring systemic treatment, or subjects who have received systemic antibiotics within 14 days before the first dose of the study intervention (Note: prophylaxis use of systemic antibiotics treatment for upper tract infection is allowed as long as there is no violation of the requirement of concomitant medications).\n   2. Known history of human immunodeficiency virus (HIV) infection and\u002For acquired immunodeficiency syndrome or positive HIV testing having CD4+ T-cell counts \\\u003C350 cells\u002FµL or subjects with unknown HIV infection status who are unwilling to undergo HIV testing.\n   3. Known active hepatitis B or C. Subjects with hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) antibody positive test results during Screening must be further tested for hepatitis B virus (HBV) deoxyribonucleic acid (DNA) titer (excluding subjects with a DNA titer of more than 2500 copies \\[cps\\]\u002FmL or 500 IU\u002FmL) and HCV ribonucleic acid (RNA) (excluding subjects with an HCV RNA concentration exceeding the lower detection limit of the assay) to exclude active hepatitis B or hepatitis C infection requiring treatment. Hepatitis B virus carriers, i.e., subjects with stable hepatitis B infection after drug treatment (DNA titer not exceeding 2500 cps\u002FmL or 500 IU\u002FmL) and hepatitis C infected subjects who received treatment and achieved sustained virologic response for at least 12 weeks can be enrolled. Note: If the lower detection limit of the HBV DNA assay is higher than 2500 cps\u002FmL or 500 IU\u002FmL, the subjects with an HBV DNA assay result lower than the lower detection limit of the assay can be enrolled.\n   4. Active tuberculosis or latent tuberculosis infection (LTBI).\n6. Known to have a history of alcoholism or drug abuse.\n7. Any other medical (e.g., Child-Pugh class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.\n8. Subjects with current pneumonitis or a history of severe pneumonitis, including but not limited to immune-related pneumonitis or radiation-induced pneumonitis.","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is an open-label, dose-escalation and dose-expansion phase Ib\u002FIIa clinical study to evaluate the safety, tolerability, and preliminary efficacy of HCB101 in combination therapies in subjects with gastric or GEJ adenocarcinoma. A total of about 40 subjects will be enrolled in this study.\n\nPart-I: Dose-Escalation Phase (Phase Ib)\n\nThis phase includes Screening, Treatment, and Follow-up Periods:\n\nScreening Period: Screening period is up to 28 days (D-28 to D-1) prior to receiving the first dose of HCB101.\n\nTreatment Period: This period includes repeat dosing treatment period (42 days per cycle). During the treatment period, subjects from different cohorts will receive HCB101 in combination therapy. Treatment will continue until one of the following occurs: unacceptable adverse event (AE), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study, whenever occurs first.\n\nFollow-up Period: This period will include Safety and Survival Follow-up Visits. After the last dose in the study, subjects are required to undergo a Safety Follow-up Visit, which will take place 30 (±7) days after the last dose of HCB101, and they will also undergo the Survival Follow-up Visit every 8 weeks (±14 days).\n\nThe end of treatment (EOT) Visit will coincide with the subject has permanently terminated the study intervention. If the EOT Visit is performed within the time window for the Safety Follow-up Visit, re-examination is not required.\n\nDose Escalation Criteria The study includes four planned dose levels of HCB101(8 mg\u002Fkg, 12 mg\u002Fkg, 18 mg\u002Fkg and 24 mg\u002Fkg) The maximum tolerated dose (MTD) will be determined using the standard 3+3 method.\n\nTo enhance safety during dose escalation, a staggered dosing approach will be applied. The second subject in each dose level should receive treatment staggered by at least 5 days after the first subject has received the 1st dose, provided that no significant safety concerns have been observed.\n\n1. Dose Escalation: The trial begins with the lowest dose, escalating in a stepwise manner. The observation period for dose limiting toxicities (DLT) is from the start of the first dose to day 28 post-dose. The next dose cohort may proceed only after the previous cohort has completed the 28-day DLT observation period and it is confirmed that the subjects are safely tolerated.\n2. Initial Cohort: Each dose cohort initially enrols three subjects. If none of these three subjects experience a DLT during the observation period, the next dose cohort will be enrolled.\n3. One DLT in a Cohort (1\u002F3): If one out of three subjects experience a DLT, an additional three subjects will be enrolled at that dose level, totally six subjects.\n\n1\\) Two or More DLTs (2+\u002F6): If one or more of the additional three subjects experience a DLT (resulting in two or more DLTs at this dose level), dose escalation will stop, and the previous dose will be designated as the MTD, or the SRC may decide to use an intermediate dose for further investigation.\n\n2\\) No Additional DLTs (1\u002F6): If none of the additional three subjects experience a DLT (resulting in one DLT out of six), the trial will proceed to the next higher dose level.\n\n4\\) Two or More DLTs in a Cohort (≥2\u002F3): If two or more out of three subjects experience a DLT, dose escalation will conclude, and the previous dose will be considered the MTD, or the SRC may determine whether to use an intermediate dose for the next level of investigation.\n\n5\\) \\*Maximum Dose Level: If the dose escalation reaches the highest level of 24 mg\u002Fkg without establishing an MTD, the MTD and\u002For the (potential) RP2D or effective dose may be confirmed based on safety, tolerability and efficacy data obtained. Additionally, it may be decided whether new dose levels are required for further escalation studies.\n\nAfter all subjects in each dose level have completed the DLT assessment, the SRC will decide whether to proceed with dose escalation, explore intermediate\u002Fhigher doses, terminate the dose escalation study, proceed with a dose extension study or adjust the tumor type for dose extension, etc., based on the data obtained on safety, tolerability and antitumor activity (if required), etc. The SRC may also adjust the dose and frequency of administration, etc.; the SRC may also decide during a dose escalation whether to adjust the tumor type enrolled. Based on the provision of a reasonable basis, appropriate methods may be used to combine the pre-adjustment data with the post-adjustment data, or with data obtained from studies conducted by HCB101.\n\nDuring the dose-escalation phase, if a subject does not experience a Grade ≥ 2 AE related to the trial treatment (including HCB101 or in combination with standard-of-care drugs), intra-subject dose escalation is permitted after the DLT evaluation period. A maximum of two intra-individual dose escalations per subject is allowed.",[28],"GC\u002FGEJC",[30,31,32],"HCB101","GC","GEJC","NOT_YET_RECRUITING","2026-07-01",{"date":36,"type":37},"2026-07-02","ACTUAL",{"date":39,"type":21},"2026-06",{"date":41,"type":21},"2027-12",{"name":43,"class":44},"Kaohsiung Medical University Chung-Ho Memorial Hospital","OTHER",{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100644535","adapted-table-tennis-for-disabilities-100644535","NCT07671807","Adapted Table Tennis for Disabilities","Health Promotion Through Adapted Table Tennis for Individuals With Disabilities","Inclusion Criteria:\n\n* Individuals aged 18 to 75 years who hold a disability identification certificate issued by the Taiwan government and have been assessed by a physician and a professional coach as suitable for participating in adapted table tennis, with a willingness to take part in the study; Participants must respond \"No\" to all questions in the first section of the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+ 2024 edition) or, if they respond \"Yes\" to one or more questions in the first section, must respond \"No\" to all questions in the second section.\n\nExclusion Criteria:\n\n* Individuals with uncontrolled cardiovascular diseases or relevant neurological history.\n* Hearing impairment.\n* Cognitive dysfunction.\n* Individuals with uncontrolled psychiatric disorders who are unable to comply with the assessments.\n* Individuals with color vision deficiencies or visual impairments.\n* Pregnant women (self-reported).\n* Individuals who have undergone lower limb musculoskeletal surgery or experienced musculoskeletal injuries within the past 6 months.\n* Individuals with a history of significant head trauma.\n* Individuals unable to comply with the testing schedule.\n* Individuals advised by a physician to avoid moderate to high-intensity exercise or those deemed unsuitable for physical activity.","75 Years",{"count":20,"type":21},[55],"NA","In recent years, sports participation among individuals with disabilities has increased, driven by medical advancements, growing societal awareness, and improved accessibility. However, a significant proportion-about 60%-still do not engage in regular physical activity, often due to limited awareness and environmental barriers. Organizations like the International Paralympic Committee (IPC) have played a key role in promoting disability sports, as evidenced by the growth in Paralympic participation from 400 athletes in 1960 to an expected 4,400 in 2024. Physical activity offers both physical and psychological benefits for people with disabilities, including improved cardiovascular health, motor function, and emotional well-being. Although adapted table tennis is a promising, accessible sport for this population, research on its health effects remains limited. This study aims to evaluate the impact of a 12-week adapted table tennis program on the physical and mental health of individuals with disabilities and to explore its potential as a sustainable health-promotion strategy.",[58],"Disability Physical",[60,61,62],"table tennis","disabilities","adapted exercise","RECRUITING","2026-06-23",{"date":66,"type":37},"2026-06-26",{"date":68,"type":37},"2025-07-08",{"date":70,"type":21},"2028-12-31",{"name":43,"class":44},1,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":88,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100641401","use-of-football-in-programs-to-reduce-stigma-toward-mental-illness-a-comparison-of-the-effectiveness-of-contact-interaction-and-video-based-approaches-100641401","NCT07658066","Use of Football in Programs to Reduce Stigma Toward Mental Illness: A Comparison of the Effectiveness of Contact Interaction and Video-Based Approaches","Inclusion Criteria:\n\n* University students currently enrolled, aged between 18 and 30 years.\n* In good physical condition with no contraindications to exercise (i.e., not diagnosed by a physician or advised to avoid physical activity, and with no items selected on the PAR-Q+ \\[Physical Activity Readiness Questionnaire for Everyone\\]).\n* Able to follow the study procedures and provide signed informed consent.\n\nExclusion Criteria:\n\n* Individuals who are unable to safely participate in football activities due to intellectual disability, pregnancy, head injury, cardiovascular disease, or other neuromuscular or musculoskeletal disorders.\n* Individuals who are unable to effectively participate in the intervention program or complete assessments due to significant emotional disturbances, personality disorders, substance (alcohol) abuse, or severe mental illness.",true,"30 Years",{"count":82,"type":21},210,[55],"The goal of this clinical trial is to evaluate the effectiveness of football-based interventions in reducing stigma toward mental illness among university students. The main questions it aims to answer are:\n\n* Does participating in a contact-based education program involving football help reduce stigma toward mental illness among university students?\n* What are the effects of three different intervention methods on reducing stigma toward mental illness?\n\nResearchers will compare the traditional contact-based education program with the other two interventions to evaluate their differences in effectiveness.\n\nParticipants will:\n\n* Be randomly assigned to one of the three intervention groups.\n* Complete online assessments to measure attitudes toward mental illness before and after the intervention.\n* Participate in qualitative interviews to provide in-depth feedback on their experiences and perceptions.",[86,87],"Psychiatry","Rehabilitation",[89,90,91,92,93],"mental illness","Psychiatric disorders","physical activity","stigma","exercise","2026-06-16",{"date":96,"type":37},"2026-06-18",{"date":98,"type":37},"2026-03-02",{"date":100,"type":21},"2027-10-31",{"name":43,"class":44},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100639467","patient-experience-of-older-adults-living-alone-with-injuries-100639467","NCT07610161","Patient Experience of Older Adults Living Alone With Injuries","Patient Experience of Older Adults Living Alone With Injuries and Long-Term Effects of Geriatric Trauma Care Program for Living Alone Older Adults With Injuries","Inclusion Criteria:\n\n1. willing to join this study for 12 weeks\n2. limb injuries,\n3. living alone without any family,\n4. 65 to 74 years old,\n5. independent before an injury,\n6. have a smart phone\n7. be able to communicate in Mandarin\n\nExclusion Criteria:\n\n1. with an ISS greater than 16 (severe injuries)\n2. severe cognitive impairment\n3. severe illness such as organ system insufficiency\n4. diagnosed with depression","65 Years","74 Years",{"count":112,"type":21},110,[55],"This study aims to explore the patient experiences of living alone older adults with injuries, and to examine the effects of a \"Geriatric Trauma Care Program\" in older adults with limb injuries who live alone. A three-year design will be used to reach the purposes of this study. The first stage of this study will use descriptive phenomenology to get patient experiences of living alone older adults with injuries. In the second stage of this study, a two-arm experimental design will be used.",[116,117,118],"Geriatrics","Trauma Injury","Living Alone","2026-05-20",{"date":121,"type":37},"2026-05-27",{"date":123,"type":37},"2023-11-22",{"date":125,"type":21},"2026-10-31",{"name":43,"class":44},2,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":79,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":72},"100628184","skincare-benefits-of-kaempferol-containing-masks-100628184","NCT07458334","Skincare Benefits of Kaempferol-Containing Masks","Clinical Evaluation of the Skincare Benefits of Kaempferol-Containing Masks","Inclusion Criteria:\n\n* Female subjects between 25 and 60 years old\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women\n* Subjects who are allergic to the product\n* Subjects with psoriasis or atopic dermatitis\n* Subjects who have taken systemic corticosteroids within 2 weeks\n* Subjects who have taken oral retinoid within 1 week\n* Subjects with severe medical conditions, such as cardiovascular, liver, kidney, or hematopoietic system disorders\n* Subjects with tuberculosis\n* Subjects with viral hepatitis or other infectious diseases\n* Subjects with psychiatric disorders\n* Subjects with external trauma or infections","FEMALE","25 Years","60 Years",{"count":139,"type":21},60,[55],"This is an open-label, two-arm study, which will evaluate the effects of Kaempferol-containing masks on skin biophysical properties",[143],"Skin Biophysical Properties","2026-03-03",{"date":146,"type":37},"2026-03-09",{"date":148,"type":37},"2026-02-09",{"date":150,"type":21},"2027-03",{"name":43,"class":44},{"id":153,"slug":154,"hasResults":12,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":165,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":72},"100481353","clinical-learning-through-extended-immersion-in-medical-simulation-cleims-a-new-approach-to-teaching-clinical-ethics-100481353","NCT05547893","Clinical Learning Through Extended Immersion in Medical Simulation (CLEIMS)-A New Approach to Teaching Clinical Ethics","Inclusion Criteria:\n\n* medical students in Kaohsiung Medical University\n* agree to participate the study\n\nExclusion Criteria:\n\n* disagree to participate",{"count":159,"type":21},600,[55],"Study objective: This study is planning to develop a new simulation-based ethics education model and evaluate the effectiveness of the model to develop medical students' knowledge, moral reasoning, communication skills, and problem-solving abilities. Several strategies will be conducted to achieve this goal, including faculty development, ethics courses development, and case scenario development.\n\nMethods: The transnational learning and workshops will be arranged for faculty to develop competence for simulation-based ethics education. The workshops will gather the interdisciplinary experts together to discuss and develop the core curriculum and case scenario. The students will be assigned randomly into the simulated clinical ethical situation with simulation patients for the intervention group, and into the workshop discussing clinical ethics case scenario for the control group. The instruments will be developed and the quantitative and qualitative analysis will be conducted.",[163,164],"Educational Activities","Patient Simulation",[166,167],"medical ethics education","simulation",{"date":169,"type":37},"2026-02-11",{"date":171,"type":37},"2020-09-29",{"date":173,"type":21},"2026-07-31",{"name":43,"class":44},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":186,"conditions":187,"keywords":192,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":72},"100619269","phase-4-high-and-low-dose-high-intensity-laser-therapy-lateral-epicondylitis-100619269","NCT07342426","High and Low Dose High-intensity Laser Therapy Lateral Epicondylitis","Comparison of the Effects of High and Low Dose High-intensity Laser Therapy in Patients With Lateral Epicondylitis","Inclusion Criteria:\n\n1. Patients diagnosed with lateral epicondylitis by physician\n2. Disease duration of less than three months\n3. Adults aged above 18 years with full decision-making capacity\n\nExclusion Criteria:\n\n1. Patients who have received treatments other than standard treatment to the affected area within past three months\n2. Patients with contraindication for rehabilitation therapy\n\n   1. Photosensitivity\n   2. Sensory impairment\n   3. Implanted cardiac pacemaker\n   4. Pregnancy\n   5. Malignancy\n3. Patients with a history of surgery on the affected elbow\n4. Patients with cervical radiculopathy",{"count":183,"type":21},45,[185],"PHASE4","High-intensity laser therapy has gained increasing attention in recent years as a therapeutic modality. It is a non-invasive treatment that can reduce pain, increase local blood circulation, and promote tissue repair. The higher energy output of high-intensity laser therapy also have deeper tissue penetration. Several studies have investigated the effects of high-intensity laser therapy on lateral epicondylitis, and the existing literature indicates that, compared with other treatment modalities, high-intensity laser therapy is more effective in improving pain and quality of life in patients with lateral epicondylitis.\n\nHowever, the dosage, duration, and treatment frequency applied in previous studies vary considerably. The therapeutic effects of high-intensity laser therapy may therefore be influenced by treatment dosage. Consequently, the purpose of this study is to compare the effects of two different dosages of high-intensity laser therapy on patients with lateral epicondylitis.",[188,189,190,191],"Lateral Epicondylitis","High Intensity Laser Therapy","Tennis Elbow","High Intensity Laser",[193],"treatment","2026-01-20",{"date":196,"type":37},"2026-01-21",{"date":198,"type":37},"2026-01-12",{"date":200,"type":21},"2026-12-06",{"name":43,"class":44},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":12,"sex":17,"minAge":208,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":218,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":228,"locationsCount":72},"100619580","exploring-the-effects-of-magnesium-ions-on-peripheral-neuropathy-serum-magnesium-ion-concentrationsleep-quality-and-quality-of-life-in-patients-with-colorectal-cancer-receiving-chemotherapy-100619580","NCT07346469","Exploring the Effects of Magnesium Ions on Peripheral Neuropathy, Serum Magnesium Ion Concentration,Sleep Quality, and Quality of Life in Patients With Colorectal Cancer Receiving Chemotherapy.","Inclusion Criteria:\n\n* a. Patients diagnosed with colorectal cancer by pathology.\n* b. Age ≥ 20 years.\n* c. Conscious.\n* d. Able to communicate fluently in Mandarin and Taiwanese.\n* e. Patients who have received or are expected to begin chemotherapy (Oxaliplatin).\n\nExclusion Criteria:\n\n* a. ECOG (Eastern Cooperative Oncology Group) ≥2 points.\n* b. Patients receiving intravenous nutrition.\n* c. Patients with pre-existing neuropathy.\n* d. Patients with skin wounds.\n* e. Patients with implanted pacemakers.\n* f. Patients with phenylketonuria.\n* g. Patients with diarrhea.\n* h. Patients with renal insufficiency.\n* i. Patients with hypermagnesemia.\n* j. Patients allergic to any of the ingredients","20 Years",{"count":210,"type":21},75,[55],"Chemotherapy for colorectal cancer (CRC) is frequently complicated by chemotherapy-induced peripheral neuropathy (CIPN) and impaired sleep quality, significantly impacting patient quality of life. Low magnesium levels have been implicated in peripheral nerve dysfunction. This interventional study aims to investigate the effects of magnesium supplementation on serum magnesium concentration, CIPN severity, and sleep quality in CRC patients undergoing chemotherapy.\n\nStudy Design and Methods\n\nThis is a prospective, parallel-group, randomized controlled trial (RCT) utilizing a longitudinal design. Participants (CRC patients undergoing chemotherapy) will be randomly allocated to one of three groups:\n\n* Experimental Group 1: Oral magnesium (400mg) supplementation.\n* Experimental Group 2: Oral magnesium (400mg}) supplementation and magnesium solution foot baths.\n* Control Group: Standard care.\n\nMeasurements will be collected using structured questionnaires and blood samples during each chemotherapy cycle. The primary outcomes will be assessed using:\n\n* Serum Magnesium Concentration\n* CIPN Severity: Functional Assessment of Cancer Therapy\u002FGynecologic Oncology Group-neurotoxicity (FACT\u002FGOG-Ntx) scale.\n* Sleep Quality: Verran and Snyder-Halpern Sleep Scale (VSH). Primary Research Questions (Hypotheses)\n\n  1. Can the magnesium intervention (oral and\u002For foot baths) effectively increase the serum magnesium concentration in CRC patients?\n  2. Can the magnesium intervention alleviate or improve the severity of CIPN?\n  3. Can the magnesium intervention improve the sleep quality of CRC patients during chemotherapy? The intervention groups will be compared against the control group to determine if the magnesium interventions lead to superior improvement in the measured outcomes.",[214,215,216,217],"Colorectal Cancer (CRC)","Chemotherapy Induced Peripheral Neuropathy (CIPN)","Sleep Quality","Quality of Life (QOL)",[219,220,216,221],"Colorectal cancer (CRC)","Chemotherapy induced peripheral neuropathy (CIPN)","Quality of life (QOL)","2026-01-07",{"date":224,"type":37},"2026-01-16",{"date":226,"type":21},"2026-01-01",{"date":70,"type":21},{"name":43,"class":44},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":244,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":4},"100616510","effectiveness-of-hydrogen-water-intervention-on-acute-oral-inflammation-oral-microbiota-and-pain-following-free-flap-reconstruction-in-patients-with-oral-cancer-100616510","NCT07306546","Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer","Inclusion Criteria:\n\n* Diagnosed with oral cancer and receiving microsurgical free flap reconstruction.\n* Age 18 years or older.\n* Conscious and able to follow study instructions.\n* Able to communicate without difficulty in Mandarin, Taiwanese, or through written communication.\n\nExclusion Criteria:\n\n* Abnormal salivary gland function or severe xerostomia.\n* Recent use of antibacterial mouthwash or antibiotic therapy that may affect oral microbiota.\n* Presence of severe bacterial or viral oral infections, or significant periodontal disease.",{"count":5,"type":21},[55],"This study employs a Randomized Controlled Trial (RCT) design. Patients diagnosed with oral cancer by the attending physician and who meet the inclusion criteria will be admitted to the study after receiving a full explanation of the study objectives, intervention methods, potential risks, and participant rights from the research team upon their stable transfer to the plastic surgery ward post-operation. Written consent will be obtained from the patient and\u002For their legally authorized representative after adequate informed consent has been provided, before they are enrolled in the study.",[239,240,241,242,243],"Oral Squamous Cell Carcinoma (OSCC)","Postoperative Pain","Postoperative Oral Mucositis","Free Flap Reconstruction","Oral Cancer",[245,246,247,248,249],"Hydrogen water","Oral cancer","Free flap reconstruction","Pain assessment","Salivary Biomarkers","2025-12-25",{"date":252,"type":37},"2025-12-29",{"date":254,"type":21},"2026-01",{"date":100,"type":21},{"name":43,"class":44},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":79,"sex":17,"minAge":4,"maxAge":263,"enrollmentInfo":264,"targetDuration":4,"studyType":22,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":277,"locationsCount":72},"100611162","evaluation-of-the-health-effects-of-the-air-purifier-in-preterm-infants-after-discharge-100611162","NCT07236996","Evaluation of the Health Effects of the Air Purifier in Preterm Infants After Discharge","Inclusion Criteria:Children aged 0 to 6 years who were born at less than 37 weeks of gestation.\n\n\\-\n\nExclusion Criteria:Children born at more than 37 weeks of gestation.\n\n\\-","6 Years",{"count":265,"type":21},180,[55],"Participant's baby was born prematurely and had underdeveloped lungs at birth. Most premature infants require mechanical ventilation after birth, which increases the risk of lung injury and may lead to varying degrees of bronchopulmonary dysplasia (BPD). Investigators believe that introducing an air purifier into your home environment after Participant's baby is discharged could help improve their lung development.\n\nThis study aims to non-invasively measure baby's transcutaneous carbon dioxide (PtcCO₂) levels and blood oxygen saturation (SpO₂) at home, both with and without the use of an air purifier. In addition, investigators will collect data from Kaohsiung Medical University Hospital medical records regarding the number of visits, respiratory status, height, weight, head circumference, and developmental progress. Health questionnaires will also be administered to assess changes in health outcomes and provide recommendations on improving indoor air quality in Participant's home.",[269,270],"Premature - Weight 1000g-2499g or Gestation of 28-37weeks","Premature Birth","2025-11-17",{"date":273,"type":37},"2025-11-19",{"date":275,"type":37},"2021-05-21",{"date":39,"type":21},{"name":43,"class":44},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":22,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":299,"locationsCount":72},"100604831","phase-4-effect-of-topical-lidocaine-spraying-on-the-vocal-cords-before-intubation-during-robotic-surgery-a-randomized-controlled-trial-100604831","NCT07154628","Effect of Topical Lidocaine Spraying on the Vocal Cords Before Intubation During Robotic Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* ASA classification I\\~III\n* aged 18\\~69 y\u002Fo\n* BMI 18\\~35 kg\u002Fm2\n* scheduled for elective robotic surgery under general anesthesia\n\nExclusion Criteria:\n\n* Allergy or contraindication to lidocaine","69 Years",{"count":286,"type":21},80,[185],"Endotracheal intubation is a respiratory management technique used during general anesthesia. It is essential for certain surgical procedures as it ensures a secure airway for the patient.\n\nHowever, during the placement of the endotracheal tube, the passage of the tube through the vocal cords can cause pain stimulation, leading to an increase in heart rate and blood pressure. Lidocaine reversibly blocks the conduction of nerve impulses along nerve fibers by preventing the movement of sodium ions across the nerve membrane. Topical application of lidocaine near the vocal cords before endotracheal tube placement may be a way to reduce the surgical pleth index and changes in vital signs (heart rate, blood pressure) caused by excessive endotracheal tube stimulation.\n\nThis study aims to investigate the benefit of topical spraying of lidocaine on the vocal cords before endotracheal tube placement during routine da Vinci surgery. The primary outcomes were the pharmacological effects of spraying either lidocaine or normal saline (control group) on the vocal cords. These included: post-intubation hypertension (defined as an increase in systolic blood pressure of more than 20% from baseline), changes in mean arterial pressure before and after intubation, and objective pain indices such as the Surgical Pleth Index. Secondary outcomes included post-intubation hypotension (defined as mean arterial pressure less than 70 mmHg), as well as postoperative complaints and severity of sore throat, pain on swallowing, and hoarseness.",[290,291,292],"Lidocaine Spray","Intubation","Robotic Surgery","2025-09-04",{"date":295,"type":37},"2025-09-11",{"date":297,"type":21},"2025-09-01",{"date":70,"type":21},{"name":43,"class":44},{"id":301,"slug":302,"hasResults":12,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":79,"sex":17,"minAge":208,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":319,"locationsCount":72},"100516936","comparison-of-effects-of-mirror-therapy-combined-with-neuromuscular-electrical-stimulation-or-binaural-beats-stimulation-on-cortical-excitability-heart-rate-variability-and-lower-limb-motor-function-in-patients-with-stroke-100516936","NCT06011018","Comparison of Effects of Mirror Therapy Combined With Neuromuscular Electrical Stimulation or Binaural Beats Stimulation on Cortical Excitability, Heart Rate Variability and Lower Limb Motor Function in Patients With Stroke","Inclusion Criteria:\n\n1. First occurrence of stroke≧ 6 months\n2. Mini-mental state examination≧24\n3. Modified Ashworth's scale of ankle muscle ≦3\n4. Sit independently≧30 mins\n5. Brunnstrom stage ≧3\n6. Aged between 20 and 80 years\n\nExclusion Criteria:\n\n1. Speech impairment\n2. Hearing impairment\n3. Visual impairment\n4. Other orthopedic diseases or nerve damage\n5. Complete sensory impairment\n6. Pacemaker or metal implants","80 Years",{"count":308,"type":21},72,[55],"This study aims to compare the effects of mirror therapy combined with either neuromuscular electrical stimulation or binaural beat stimulation on post-stroke lower limb motor function recovery. The study also explores the relationship between patients' cortical excitability and motor function improvement.",[312,313],"Stroke","Healthy Adults","2025-08-27",{"date":293,"type":37},{"date":317,"type":37},"2022-10-25",{"date":173,"type":21},{"name":43,"class":44},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":17,"minAge":208,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":22,"phases":330,"briefSummary":331,"conditions":332,"keywords":334,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":340,"startDateStruct":341,"completionDateStruct":342,"leadSponsor":344,"locationsCount":4},"100604814","ai-assisted-masticatory-muscle-training-in-patients-with-schizophrenia-100604814","NCT07154407","AI-assisted Masticatory Muscle Training in Patients With Schizophrenia","The Effectiveness of AI-assisted Masticatory Muscle Training on Oral Hygiene, Masticating, and Swallowing in Patients With Schizophrenia","AI-assisted","Inclusion Criteria:\n\n* Psychiatric Outpatient Ward Schizophrenia Diagnosed patient with 20 years or above\n* Without Violence or suicidal tendencies\n* With a self-owned smartphone\n* Able to stabilise the IOPI machine while testing\n* Able to communicate\n\nExclusion Criteria:\n\n* Severe psychiatric symptoms\n* With medical history which affects oral hygiene and masticating function severely (such as stroke, oral cavity-related cancer, periodontitis)\n* Severe cognitive function with a score of less than 16 marks in the MoCA Test\n* Indicated with Motor Neuron Disease\n* Joining multiple Intervention Experiments simultaneously",{"count":329,"type":21},100,[55],"Dysphagia seems to be quite common and potentially severe in schizophrenia, which may lead to acute asphyxia or pneumonia. Dysphagia in schizophrenia could be associated with drug-induced Parkinsonism, dystonia, tardive dyskinesia, dry mouth, excessive saliva, and other complications. Inadequate oral hygiene may lead to the accumulation of plaque, which can cause oral diseases and consequently result in tooth loss. This could be one of the significant factors affecting impaired masticating and swallowing abilities.\n\nAn experimental study with random assignment will be adopted. The participants from 2 hospitals will be assigned to two groups: experimental group (n=50), and control group (n=50). The experimental group will receive 'AI-assisted Masticatory Muscle Training' sessions, each lasting 20 minutes, before each of their three daily meals. The plaque index, Winkle tongue-coating index, dry mouth, repetitive saliva swallowing, saliva flow rate, biting force, tongue pressure, oral frailty, RSST, DDK, and oral care behaviors were assessed at baseline, as well as during the 3-month follow-ups.",[333],"Schizophrenia Disorder",[335,326,336,337,338],"Masticatory Muscle Training","Oral Hygiene","Masticate","Swallow","2025-08-26",{"date":293,"type":37},{"date":295,"type":21},{"date":343,"type":21},"2027-12-31",{"name":43,"class":44},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":17,"minAge":352,"maxAge":208,"enrollmentInfo":353,"targetDuration":4,"studyType":22,"phases":354,"briefSummary":355,"conditions":356,"keywords":362,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":339,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":72},"100566135","decision-support-intervention-of-minor-cancer-patients-and-their-parents-100566135","NCT06651242","Decision Support Intervention of Minor Cancer Patients and Their Parents","Effectiveness Evaluation on the Decision Preferences and Decision Support Intervention of Minor Cancer Patients and Their Parents","Inclusion Criteria:\n\n* Inclusion Criteria for Parents:\n\n  1. Age over 20 years.\n  2. Child under 20 years old, diagnosed with cancer by a doctor.\n  3. their child know her\u002Fhis cancer diagnosis.\n  4. Agree to have the child participate in family meeting and have ability to communicate in Mandarin or Taiwanese.\n* Inclusion Criteria for Minors:\n\n  1. Aged between 7 and 20 years, diagnosed with pediatrtic cancer.\n  2. Aware of their cancer diagnosis.\n  3. Able to express their thoughts to the researcher in Mandarin or Taiwanese.\n  4. Both the minor and their legal guardian consent to participate in the study.\n\nExclusion Criteria:\n\n1. Diagnosed with depression, and\u002For anxiety, and\u002For other mental disorders.\n2. Legal guardian is unwilling to inform the minor of their diagnosis.\n3. Minor is unwilling to share their thoughts with their parents.","7 Years",{"count":286,"type":21},[55],"The purpose of this stuidy are: (1) to explore the information needs of parents having children with cancer when making treatment decisions; (2) to develop a Taiwan version of the Control Preferences Scale for decision support aids; (3) to implement and evaluate the effectiveness of involving minor cancer patients and their parents in treatment decision-making.",[357,358,359,360,361],"Pediatric Cancer","Adolescent Health","Decision Aids","Parents of Children With Cancer","Decision Making ,Shared",[363,364,365,366,367],"Minor Cancer","Parents","Decision Preferences","Decision Support","Intervention",{"date":369,"type":37},"2025-08-28",{"date":371,"type":37},"2022-10-26",{"date":373,"type":21},"2027-07-31",{"name":43,"class":44},{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":79,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":384,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":392,"leadSponsor":393,"locationsCount":4},"100602663","effects-of-an-exercise-snack-intervention-on-employee-health-and-work-performance-100602663","NCT07126444","Effects of an Exercise Snack Intervention on Employee Health and Work Performance","Effects of an Exercise Snack Intervention on Employee Health and Work Performance: A Study at Kaohsiung Medical University","Inclusion Criteria:\n\n1. Currently employed at Kaohsiung Medical University or Kaohsiung Medical University Hospital.\n2. Willing to participate in a 12-week exercise intervention, complete related questionnaires, and undergo physical performance assessments.\n\nExclusion Criteria:\n\n1. Pregnant individuals, due to safety concerns related to exercise intensity and physical assessments.\n2. Individuals with a diagnosed neurological disorder (e.g., stroke, Parkinson's disease).\n3. Individuals experiencing severe pain in the upper or lower limb joints that interferes with their ability to complete the assessments.\n4. Individuals assigned to high-intensity exercise who have unstable cardiac conditions (e.g., angina, myocardial infarction, heart failure).",{"count":383,"type":21},130,"OBSERVATIONAL","To create brief exercise videos addressing physical discomfort, fitness goals, and movement skills.\n\nTo design personalized exercise menus to enhance staff adherence.\n\nTo apply the \"exercise snacking\" model with multiple short daily sessions and evaluate its effects on health, work performance, and exercise behavior.",[387],"Occupational Stress","2025-08-24",{"date":390,"type":37},"2025-08-29",{"date":390,"type":21},{"date":343,"type":21},{"name":43,"class":44},{"id":395,"slug":396,"hasResults":12,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":401,"enrollmentInfo":402,"targetDuration":4,"studyType":384,"phases":4,"briefSummary":404,"conditions":405,"keywords":412,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":72},"100426368","bio-significance-of-lpc160-in-fibromyalgia-100426368","NCT04832100","Bio-significance of LPC16:0 in Fibromyalgia","A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia","Inclusion Criteria:\n\n1\\. Clinical diagnosis of fibromyalgia\n\nExclusion Criteria:\n\n1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis),\n2. Systemic use of corticosteroids,\n3. Pregnancy,\n4. Chronic diseases under poor control\n5. Malignancies.","70 Years",{"count":403,"type":21},245,"Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far.\n\nIn this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.",[406,407,408,409,410,411],"Fibromyalgia, Primary","Pain","Soreness, Muscle","Oxidative Stress","Metabolomics","Lipidomics",[413,414,415,416,417],"lysophosphotidylcholine","fibromyalgia","pain","soreness","metabolomics","2025-06-22",{"date":420,"type":37},"2025-06-26",{"date":422,"type":37},"2021-06-01",{"date":424,"type":21},"2027-06-30",{"name":43,"class":44},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":433,"targetDuration":4,"studyType":22,"phases":435,"briefSummary":436,"conditions":437,"keywords":439,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":443,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":448,"locationsCount":72},"100582419","brain-tumor-surgery-and-postoperative-delirium-100582419","NCT06863064","Brain Tumor Surgery and Postoperative Delirium","Exploring the Effects of Perioperative Dexmedetomidine on the Incidence of Postoperative Delirium, Acute and Chronic Pain, and Sleep Quality in Patients Undergoing Brain Tumor Surgery","Inclusion Criteria:\n\n* at least 18 years old and less than 80 years old\n* receive brain tumor surgery with ASA II\\~III.\n\nExclusion Criteria:\n\n* under the age of 18 or over 80\n* consciousness unclear\n* those who have not signed a consent form\n* those with high anesthesia risk ASA IV or higher",{"count":434,"type":21},140,[55],"1. To explore whether the combined administration of dexmedetomidine during and after surgery in patients undergoing brain tumor resection is an effective and safe modality to prevent postoperative delirium and improve sleep quality than giving it alone after surgery.\n2. To explore whether intraoperative and postoperative administration of dexmedetomidine to patients undergoing brain tumor surgery can reduce postoperative acute pain and prevent chronic pain.\n3. To explore whether intraoperative and postoperative administration of dexmedetomidine to patients undergoing brain tumor surgery can provide stable anesthesia depth, hemodynamics and reduce the dose of anesthetics, thereby accelerating patient recovery.",[438],"Brain Tumor",[440,441],"brain tumor","postoperative delirium","2025-03-04",{"date":444,"type":37},"2025-03-07",{"date":446,"type":21},"2025-03-01",{"date":343,"type":21},{"name":43,"class":44},{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":79,"sex":17,"minAge":456,"maxAge":109,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":459,"briefSummary":460,"conditions":461,"keywords":465,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":442,"lastUpdatePostDateStruct":469,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":474,"locationsCount":72},"100511340","the-effects-of-using-augmented-reality-ar-system-to-train-foreign-care-workers-100511340","NCT05938166","The Effects of Using Augmented Reality (AR) System to Train Foreign Care Workers.","The Effects of Using Augmented Reality (AR) System to Train Foreign Care on Salivary Biomarker and Oral Function of the Elderly People","Inclusion Criteria:\n\n* 1\\. The Indonesian caregivers who are employed in Kaohsiung City are aged between 21 and 65 and have simple Chinese communication skills.\n* 2\\. The elderly people being cared for is over 65 years old.\n\nExclusion Criteria:\n\n* 1\\. Elderly people who are unable to cooperate with instructions.\n* 2\\. Elderly people with facial impairment.","21 Years",{"count":458,"type":21},42,[55],"The aim of this study was to evaluate the effect of augmented reality (AR) system training intervention of foreign care workers on the salivary biomarker and oral function of older people.\n\nThis randomized controlled trial included experimental group: AR group (EG-A) Video group (EG-B) and control group(CG), respectively. The EG-A will receive augmented reality (AR) system training intervention with AR tooth-cleaning skills session course add video-based oral hygiene education course . The EG-B receive video-based oral hygiene education course and The CG only receive only a leaflet.",[462,463,464],"Oral Dryness and Saliva Altered","Oral Manifestations","Swallowing Disorder",[466,467,468],"AR (augmented reality)","Oral Care Behavior","Saliva Biomarker",{"date":444,"type":37},{"date":471,"type":37},"2024-01-03",{"date":473,"type":21},"2026-12-31",{"name":43,"class":44},{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":22,"phases":484,"briefSummary":485,"conditions":486,"keywords":491,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":72},"100581954","evaluating-the-clinical-effectiveness-of-endotracheal-tube-position-anomaly-alerting-system-100581954","NCT06857019","Evaluating the Clinical Effectiveness of \"Endotracheal Tube Position Anomaly Alerting System\"","ETPAAS-1","Inclusion Criteria:\n\n* Patients admitted to the intensive care unit\n* At least 18 years old\n\nExclusion Criteria:\n\n* Patients disagree to participate in the study",{"count":483,"type":21},200,[55],"The goal of this clinical trial is to determine whether the Endotracheal Tube Position Anomaly Alerting System (ETPAAS) effectively reduces the duration of endotracheal tube malposition in patients admitted to the intensive care unit (ICU). Additionally, the study will assess the clinical impact, usability, and user satisfaction of ETPAAS.\n\nThe main questions it aims to answer are:\n\n* Does ETPAAS reduce the duration of endotracheal tube malposition?\n* What are healthcare workers' perspectives on the usability and satisfaction of ETPAAS?\n\nParticipants will receive standard care, with or without ETPAAS, in the intensive care unit.\n\nResearchers will evaluate the duration of endotracheal tube malposition. Healthcare workers will complete a questionnaire assessing the usability and satisfaction of ETPAAS.",[487,488,489,490],"Critical Care Medicine","Mechanical Ventilation","Radiographic Image Interpretation, Computer-Assisted","Alarms",[492,493,494,495],"Chest X-ray","Chest radiograph","Endotracheal tube","Intubation, Intratracheal","2025-02-26",{"date":442,"type":37},{"date":499,"type":21},"2025-02-24",{"date":501,"type":21},"2025-12-31",{"name":43,"class":44},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":509,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":514,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":523,"locationsCount":4},"100580478","phase-4-to-explore-the-optimal-dose-of-dexmedetomidine-for-skull-pin-fixation-in-intracranial-surgery-100580478","NCT06837818","To Explore the Optimal Dose of Dexmedetomidine for Skull Pin Fixation in Intracranial Surgery","Inclusion Criteria:\n\n* Must be at least 18 years old and less than 80 years old, with ASA I\\~III. Patients who are expected to undergo intracranial surgery for skull pin fixation.\n\nExclusion Criteria:\n\n* Patients under the age of 18, patients over 80, those who have not signed a consent form, those with ASA class IV or higher, those who are allergic to dexmedetomidine or propofol or remifentanil, sever bradycardia (HR\\\u003C40 bpm), hypotension (\\\u003C90\u002F60 mmHg) and hypertension crisis (180\u002F110 mmHg), and emergency patients, etc.",{"count":20,"type":21},[185],"Skull pin fixation is commonly used in intracranial surgery, which can increase the surgical field of view. Because skull pin fixation is a very irritating and painful medical treatment, it often results in tachycardia (\\>150-160 beats per min, bpm) and high blood pressure (BP) (\\>200\u002F120 mmHg). Many strategies to reduce this painful stimulation include oral gabapentin, local injection of local anesthetics, scalp nerve blockade, and deepening the depth of anesthesia. Oral gabapentin must take 2 hr before surgery with many adverse effects such as nausea and vomiting. Local injection of local anesthetics and scalp nerve blockade require injections by neurosurgeons. Due to the manpower and time constraints, neurosurgeons cannot perform the two techniques. Therefore, it depends on anesthesiologists to prescribe more anesthetics to attenuate this intensity painful stimulation. Usually anesthesiologists will give propofol, opioids (fentanyl, alfentanil or remifentanil), α2 agonist (dexmedetomidine or clonidine), add inhalation anesthetics (sevoflurane or desflurane), and finally even use b-blocker to reduce hemodynamic instability (hyperdynamics).\n\nDexmedetomidine mainly produces a sedative effect by activating α2 adrenergic receptors in the central nervous system. Its α2:α1 ratio is 1620:1, showing high affinity for α2 receptors. Unlike other hypnotic drugs during death, dexmedetomidine keeps the patient in an awakenable state and does not affect respiratory function during sedation. Therefore, general anesthesia can be enhanced, providing sedation and analgesia and improving sleep quality.\n\nTarget-controlled infusion (TCI) pump systems can automatically adjust drug infusion rates based on the patient's weight, age, and other physiological parameters to achieve more precise drug concentrations. It can maintain a stable drug concentration and reduce the impact of drug fluctuations on patients, especially when long-term anesthesia or sedation is required. Therefore, using a TCI pump system to administer dexmedetomidine can ensure that the concentration we want can be accurately achieved when performing skull pin fixation. Our hospital has routinely used the Dyck mode of the TCI pump system to infuse dexmedetomidine 0.2-0.4 ng\u002Fml during intracranial surgery.\n\nIn view of this, we wanted to observe patients undergoing intracranial surgery with skull pin fixation using the Dyck mode by the TCI pump system under the monitoring of analgesic nociceptive index and hemodynamics. In order to find out the most appropriate dexmedetomidine concentration during skull pin fixation to reduce hemodynamic fluctuations and insufficient pain management as a basis for future anesthesia.",[513],"Procedural Pain",[515,516,517],"Skull pin fixation","dexmedetomidine","Target-controlled infusion","2025-02-19",{"date":520,"type":37},"2025-02-20",{"date":446,"type":21},{"date":501,"type":21},{"name":43,"class":44},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":17,"minAge":208,"maxAge":531,"enrollmentInfo":532,"targetDuration":4,"studyType":22,"phases":533,"briefSummary":534,"conditions":535,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":72},"100579576","phase-2-metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy-100579576","NCT06826092","Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy","Metformin as an Adjunctive Therapy for the Treatment of Metastatic Colorectal Cancer Patients Undergoing FOLFIRI Plus Target Therapy","Inclusion Criteria:\n\n1. Aged between 20 and 90 years old\n2. Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy\n3. Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)\n4. Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)\n5. Those who are not allergic to the relevant drugs required for the test\n6. Those who can follow the doctor's order to take the medicine\n7. Subjects must be willing to sign the consent form\n8. Blood sugar level above 80 mg\u002FdL\n\nExclusion Criteria:\n\nSubjects who meet any of the following exclusion conditions are not allowed to join the trial\n\n1. Patients other than the above-mentioned main inclusion criteria.\n2. Non-native speakers\n3. Known allergy to metformin or any of its components.\n4. Severe instability in diabetes (ketoacidosis).\n5. Blood sugar level lower than 80 mg\u002FdL\n6. Heart failure, respiratory insufficiency.\n7. inadequate hematopoietic function defined as below:\n\n   * hemoglobin \\\u003C 9 g\u002FdL;\n   * absolute neutrophil count (ANC) \\\u003C 1,500\u002Fmm3;\n   * platelet count \\\u003C 100,000\u002Fmm3;\n8. inadequate organ functions defined as below:\n\n   * total bilirubin \\> 2 times upper limit of normal (ULN);\n   * hepatic transaminases (ALT and AST) \\> 2.5 x ULN;\n   * creatinine \\> 1.5 x ULN;","90 Years",{"count":112,"type":21},[25],"To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin",[536],"Progression-Free Survival","2025-02-10",{"date":539,"type":37},"2025-02-13",{"date":541,"type":37},"2022-10-31",{"date":501,"type":21},{"name":43,"class":44},{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":550,"maxAge":109,"enrollmentInfo":551,"targetDuration":4,"studyType":22,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":566,"locationsCount":72},"100522517","the-dental-care-revolution-health-education-using-ai-or-humanized-counseling-on-plague-control-and-periodontal-treatment-outcome-in-patients-with-periodontal-disease-100522517","NCT06083649","The Dental Care Revolution: Health Education Using AI or Humanized Counseling on Plague Control and Periodontal Treatment Outcome in Patients With Periodontal Disease","Inclusion Criteria:\n\n* Age between 35-65 years old\n* Diagnosed periodontal disease by dentist (Comprehensive Periodontal Treatment Project)\n* More than 16 functional teeth\n\nExclusion Criteria:\n\n* Have received periodontal treatment within 3 months\n* Patient has disease related to periodontal disease (ex. Drug-related excessive gum growth or blood clotting problems, pregnancy, mental illness)\n* Disability patients","35 Years",{"count":329,"type":21},[55],"The aim of this study was to evaluate the long-term effectiveness of an AI dental monitoring intervention on patients' periodontal disease, preventive behaviors and motivation. This randomized controlled trial included experimental group: AI group (EG-A), AI-humanized group (EG-B) and control group(CG), respectively.\n\nThe EG-A and EG-B received AI dental monitoring intervention by taking mouth image at home once a week for six month. Baseline and follow-up surveys were used to collect the data in oral health related quality of life,periodontal parameters, periodontal preventive behaviors and motivation.",[555],"Periodontal Diseases",[557,558,559],"periodontal disease","artificial intelligence (AI)","OHRQoL","2025-02-04",{"date":562,"type":37},"2025-02-06",{"date":564,"type":37},"2020-08-10",{"date":501,"type":21},{"name":43,"class":44},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":12,"sex":17,"minAge":550,"maxAge":109,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":573,"briefSummary":574,"conditions":575,"keywords":576,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":584,"locationsCount":72},"100406025","using-artificial-intelligence-platform-on-plaque-control-and-periodontal-treatment-outcome-in-patients-with-periodontal-disease-preliminary-results-100406025","NCT04567030","Using Artificial Intelligence-platform on Plaque Control and Periodontal Treatment Outcome in Patients With Periodontal Disease-Preliminary Results",{"count":329,"type":21},[55],"The aim of this study was to evaluate the long-term effectiveness of an AI dental monitoring intervention on patients' periodontal disease, preventive behaviors and motivation. This randomized controlled trial included experimental group: AI group (EG-A), AI-humanized group (EG-B) and control group(CG), respectively.\n\nThe EG-A and EG-B received AI dental monitoring intervention by taking mouth image at home once a week for six month.\n\nBaseline and follow-up surveys were used to collect the data in periodontal index, periodontal preventive behavior and motivation.",[555],[577,578,579,555],"oral hygiene","artificial intelligence","Periodontitis",{"date":562,"type":37},{"date":582,"type":37},"2019-11-16",{"date":501,"type":21},{"name":43,"class":44},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":592,"targetDuration":4,"studyType":22,"phases":593,"briefSummary":594,"conditions":595,"keywords":597,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":4},"100575661","fiberoptic-bronchoscopy-on-supraglottic-airway-devices-position-100575661","NCT06775184","Fiberoptic Bronchoscopy on Supraglottic Airway Devices Position","The Effect of Fiberoptic Bronchoscopy Examination on Supraglottic Airway Devices Position in Patients Undergoing Elective Surgery","Inclusion Criteria:\n\n* ASA classification I\\~III, age 18\\~65 y\u002Fo, BMI 18\\~30kg\u002Fm2, elective surgery, surgery duration \\\u003C 2 hours, supine position, general anesthesia with laryngeal mask airway insertion\n\nExclusion Criteria:\n\n* Smoking, betel nuts use, any known anatomical variation or disease of facial or airway structure, anticipated difficult airway, limited mouth opening distance or neck motility, loosening teeth, gastroesophageal reflux history, ongoing upper airway infection or inflammation symptoms",{"count":286,"type":21},[55],"A comparison of SaCo VLMTM video laryngeal mask airway with the I-gel supraglottic airway during airway management in patients undergoing elective surgery.",[596],"Supraglottic Airway Devices Position",[598,599,600],"supraglottic device","video laryngeal mask","fiberoptic bronchoscopy","2025-01-09",{"date":603,"type":37},"2025-01-15",{"date":605,"type":21},"2025-02",{"date":607,"type":21},"2026-12",{"name":43,"class":44},{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":79,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":615,"targetDuration":4,"studyType":22,"phases":616,"briefSummary":617,"conditions":618,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":626,"locationsCount":72},"100573795","optimizing-third-generation-video-laryngeal-mask-position-sacovlm-vs-fiberoptic-bronchoscope-100573795","NCT06750926","Optimizing Third-Generation Video Laryngeal Mask Position: SaCoVLM™ vs. Fiberoptic Bronchoscope","Optimal Position of the Third Generation Video Laryngeal Mask Airway: to Compare Visualization of the SaCoVLMTM Videoscope With the Traditional Fiberoptic Bronchoscope",{"count":20,"type":21},[55],"This study aims to compare the effectiveness of SaCoVLM™ in artificial airway ventilation during general anesthesia, focusing on the correlation between native video camera imaging and fiberoptic endoscopy. Primary outcomes include the analysis of imaging correlation, while secondary outcomes assess initial placement success rates, difficulty, blood clot adherence, vital sign changes, and postoperative complications.",[619],"Supraglottic Airway Device","2024-12-25",{"date":622,"type":37},"2024-12-27",{"date":624,"type":21},"2025-01-01",{"date":173,"type":21},{"name":43,"class":44},""]